AI reading of ECGs to find occlusion myocardial infarction
Official title: Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
Run by Cardiocentro Ticino · NCT07077057 · Data updated 2026-11-12
This trial tests whether an AI tool that reads ECGs can help doctors identify and treat occlusion myocardial infarction faster in adults with suspected acute coronary syndrome who don't meet STEMI criteria.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Cardiocentro Ticino Academic / other |
| Locations | 1 site (Lugano, Canton Ticino) |
| Status | Recruiting |
| Started | August 23, 2025 |
| Main results expected | August 2027 |
| Study ends | September 2027 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT07077057 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who present with symptoms of acute coronary syndrome within 24 hours, do not meet clinical STEMI criteria, and can provide informed consent are ideal candidates.
✕Probably not a fit
Patients with a clear STEMI diagnosis, those presenting more than 24 hours after symptom onset, pregnant or lactating individuals, and those unable to consent are unlikely to receive benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults presenting with symptoms of acute coronary syndrome but without clear ST-elevation are randomized 1:1 to have their ECG interpreted with an AI tool (PMcardio) or to standard care. The study compares time to coronary intervention and infarct size, with infarct size measured by peak high-sensitivity troponin T (hsTnT). Key eligibility includes age 18+, symptom onset within 24 hours, and ability to give informed consent, while patients with a clear STEMI diagnosis, pregnancy/lactation, or legal incapacity are excluded. The trial is conducted at Cardiocentro Ticino in Lugano and focuses on care timelines and biomarker outcomes between the two arms.
Why it matters
Potential benefit: If successful, the AI tool could speed diagnosis and treatment of occlusion MIs, potentially reducing heart muscle damage and improving recovery.
How similar studies have gone: Prior studies of AI ECG algorithms have shown promise in detecting acute ischemia and hidden myocardial infarction, but randomized evidence specifically for occlusion MI detection remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder/arm/jaw/back, fatigue, or light-headedness 2. Age: Patients aged 18 years or older. 3. Informed Consent: Patients able to provide informed consent Exclusion Criteria: 1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians. 2. Pregnancy or Lactation. 3. Legally incompetent to provide informed consent. 4. Symptoms onset\>24 hrs prior to clinical presentation.
Where it's running
-
Cardiocentro Ticino Institute
Lugano, Canton Ticino, Switzerland Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Optimal timing of staged complete revascularization in STEMI with multivessel disease
This trial tests whether performing staged complete revascularization during the hospital stay or after discharge is best for STEMI patients with multivessel disease.
-
BEAT-SHOCK: Baseline Registry for Acute Cardiogenic Shock at Basel
This registry collects and shares data on adults with cardiogenic shock admitted to University Hospital Basel to help understand how these patients are treated and how they fare.
-
Low-dose IL-2 after heart attack to study tissue-resident regulatory T cells
Researchers are testing whether low-dose interleukin-2 given after a myocardial infarction can boost tissue-resident regulatory T cells to support heart repair.
-
Abbreviated antithrombotic therapy after PCI in AF and MI
This trial tests whether DOAC-only therapy works as well as DOAC plus clopidogrel after PCI in people with atrial fibrillation and a recent heart attack.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.